SCHEMBL4603638

SCHEMBL4603638

Cc1ccc(N)cc1OC1CCN(C(=O)c2ccccc2Cl)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.52
RAB9A P51151 1/20 0.51
GAA P10253 1/20 0.48
HRH1 P35367 1/20 0.47
CCR3 P51677 1/20 0.47
MGLL Q99685 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTR2B P41595 1/20 0.46
MAPK14 Q16539 1/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HSD11B1 P28845 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
EPHX2 P34913 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603720 0.83 RAB9A (0.59) RAB9AGAAHRH1CCR3MGLL
SCHEMBL6569244 0.77 HRH1 (0.59) PDE4BRAB9AGAAHRH1CCR3
SCHEMBL21381457 0.77 ALDH1A1 (0.60) GAATDP1ALDH1A1
SCHEMBL29634995 0.77 ALDH1A1 (0.60) GAATDP1ALDH1A1
SCHEMBL24590609 0.75 RAB9A (0.55) PDE4BRAB9AGAAHRH1CCR3
SCHEMBL20695969 0.75 KDM1A (0.53) PDE4B
SCHEMBL6569293 0.74 CCR3 (0.65) PDE4BRAB9AGAAHRH1CCR3
SCHEMBL4491187 0.73 HRH3 (0.44) HRH1HTR2BALDH1A1KDM4E
SCHEMBL5318563 0.72 EPHX2 (0.52) GAAHRH1CCR3HSD11B1EPHX2
SCHEMBL5864797 0.72 RORC (0.50) PDE4BRAB9AHRH1CCR3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767674-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2010-08-03 US disclosed
US-7767674-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2010-08-03 US disclosed
US-20080306068-A1 Suppression cytokines, tumor necrosis factor ELI LILLY AND COMPANY (US) 2008-12-11 US disclosed
US-20080306068-A1 Suppression cytokines, tumor necrosis factor ELI LILLY AND COMPANY (US) 2008-12-11 US disclosed
EP-1761520-B1 KINASE INHIBITORS LILLY CO ELI (US) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306068-A1 Suppression cytokines, tumor necrosis factor TNF, TNFRSF1A, IL2 PDE4B 1895/4885RAB9A 3581/4885GAA 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.